{"disease":{"id":"low-risk-myelodysplastic-syndrome","name":"low risk myelodysplastic syndrome"},"drugs":{"marketed":[{"drug_id":"imetelstat","indication_name":"low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02958462","title":"Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07465029","title":"A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06298643","title":"Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03824080","title":"Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT04718844","title":"A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Silence Therapeutics plc","has_results":false},{"nct_id":"NCT06614595","title":"Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Fundación para la Investigación Biosanitaria del Principado de Asturias","has_results":false},{"nct_id":"NCT01868477","title":"Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05903274","title":"JSP191 (briquilimab) in Subjects with LR-MDS","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Jasper Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04176653","title":"Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Silence Therapeutics plc","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}